Please Wait...

OPN / / Osteopontin

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Identified in bone calcified matrix, Osteopontin (OPN) is also called Bone Sialoprotein I and belongs to the Small Integrin-Binding Ligand, N-linked Glycoprotein (SIBLING) family of protein (Franzen and Heinegard, 1985). OPN contain an RGD motif which allow interaction with integrins and cell surface receptors (Oldberg et al., 1986). OPN interacts with various other partners, can be cleaved by thrombin and in some conditions also by MMP-3 and MMP-7. The resulting fragments have then specific properties which result in modulation of cell migration and adhesion (Bellahcène et al., 2008). Due to its proprieties, OPN is implicated in tumor progression but also in skeletal disorders (Ramchandani and Weber, 2015; Rittling and Chambers, 2004).

Bioclinica Lab employs a manual sandwich immunoassay for the measurement of OPN in plasma.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Still time to catch up on summer reading on recent developments in #Alzheimer's Disease Fluid Biomarkers here int t… https://t.co/kyQmz7FxlN
bioclinica (Yesterday)
Our clients have substantial success w #eSource, some spanning well over a decade. Still other organizations remain… https://t.co/UwVs6ajPp4
bioclinica (2 days ago)
Our clients have substantial success w #eSource, some spanning well over a decade. Still some in the industry remai… https://t.co/ASuUvN6xb9
bioclinica (4 days ago)
RT @RfwrightLSL: When Do You Think #BYOD (Bring Your Own Device) Will Become Widely Used To Capture PRO Data In #Clinical #Research? https:…
bioclinica (1 week ago)
ICYMI: Our V.P./Head of Neuroscience & Cardiovascular Svcs., Dr. Joyce Suhy, talks about challenges in determining… https://t.co/Lns6B3VPPN
bioclinica (1 week ago)
RT @FCR_News_Today: FDA Issues New Guides on Use of Electronic Health Information in #ClinicalTrials. #ClinicalResearch https://t.co/j8LHV2…
bioclinica (2 weeks ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen